Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAR-Ts May Be Closer Competitors To Lilly’s Jaypirca Than Fellow BTK Inhibitors

Executive Summary

The Loxo@Lilly drug got FDA accelerated approval in mantle cell lymphoma as the first non-covalent BTK inhibitor, enabling its use in post-BTKi disease.

You may also be interested in...



Lilly’s Latest Leadership Shuffle Gives CSO Skovronsky Immunology Oversight

Lilly Diabetes president Mike Mason is retiring, prompting a shifting of responsibilities among the executive team as the company gears up for key product approvals. 

Lilly Sales Swing Back As Pandemic, Loss Of Exclusivity Pressures Recede

The drug maker is looking ahead to potentially big approvals of donanemab for Alzheimer’s disease and Mounjaro for obesity by the end of the year.

Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market

Excluding COVID-19 antibodies, the company said revenues for the quarter increased by 10% while volume increased by 18%, and sales of Mounjaro came in stronger than analysts anticipated.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel